Cite
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min
MLA
Ross, Lisa L., et al. “Changes over Time in Creatinine Clearance and Comparison of Emergent Adverse Events for HIV-Positive Adults Receiving Standard Doses (300 Mg/Day) of Lamivudine-Containing Antiretroviral Therapy with Baseline Creatinine Clearance of 30–49 vs ≥50 ML/Min.” PLoS ONE, vol. 14, no. 11, Nov. 2019, pp. 1–14. EBSCOhost, https://doi.org/10.1371/journal.pone.0225199.
APA
Ross, L. L., Walker, A. S., Lou, Y., Tenorio, A. R., Gibb, D. M., Double, J., Gilks, C., McCoig, C. C., Munderi, P., Musoro, G., Kityo, C. M., Grosskurth, H., Hakim, J., Mugyenyi, P. N., Cutrell, A., Perger, T., & Shaefer, M. S. (2019). Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min. PLoS ONE, 14(11), 1–14. https://doi.org/10.1371/journal.pone.0225199
Chicago
Ross, Lisa L., A. Sarah Walker, Yu Lou, Allan R. Tenorio, Diana M. Gibb, Julia Double, Charles Gilks, et al. 2019. “Changes over Time in Creatinine Clearance and Comparison of Emergent Adverse Events for HIV-Positive Adults Receiving Standard Doses (300 Mg/Day) of Lamivudine-Containing Antiretroviral Therapy with Baseline Creatinine Clearance of 30–49 vs ≥50 ML/Min.” PLoS ONE 14 (11): 1–14. doi:10.1371/journal.pone.0225199.